Biomarin Pharmaceutical Inc (BMRN)
80.94
-1.23
(-1.50%)
USD |
NASDAQ |
Apr 26, 16:00
82.00
+1.06
(+1.31%)
After-Hours: 20:00
Biomarin Pharmaceutical Revenue (Quarterly): 646.21M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 646.21M |
| September 30, 2023 | 581.33M |
| June 30, 2023 | 595.28M |
| March 31, 2023 | 596.42M |
| December 31, 2022 | 537.54M |
| September 30, 2022 | 505.34M |
| June 30, 2022 | 533.80M |
| March 31, 2022 | 519.36M |
| December 31, 2021 | 449.81M |
| September 30, 2021 | 408.74M |
| June 30, 2021 | 501.69M |
| March 31, 2021 | 486.03M |
| December 31, 2020 | 452.12M |
| September 30, 2020 | 476.78M |
| June 30, 2020 | 429.48M |
| March 31, 2020 | 502.04M |
| December 31, 2019 | 454.44M |
| September 30, 2019 | 461.10M |
| June 30, 2019 | 387.76M |
| March 31, 2019 | 400.74M |
| December 31, 2018 | 353.26M |
| September 30, 2018 | 391.71M |
| June 30, 2018 | 372.84M |
| March 31, 2018 | 373.45M |
| December 31, 2017 | 358.30M |
| Date | Value |
|---|---|
| September 30, 2017 | 334.15M |
| June 30, 2017 | 317.45M |
| March 31, 2017 | 303.74M |
| December 31, 2016 | 300.09M |
| September 30, 2016 | 279.90M |
| June 30, 2016 | 300.13M |
| March 31, 2016 | 236.74M |
| December 31, 2015 | 227.94M |
| September 30, 2015 | 208.90M |
| June 30, 2015 | 250.14M |
| March 31, 2015 | 202.92M |
| December 31, 2014 | 230.07M |
| September 30, 2014 | 176.55M |
| June 30, 2014 | 191.79M |
| March 31, 2014 | 151.55M |
| December 31, 2013 | 146.87M |
| September 30, 2013 | 136.87M |
| June 30, 2013 | 136.81M |
| March 31, 2013 | 127.93M |
| December 31, 2012 | 131.94M |
| September 30, 2012 | 128.12M |
| June 30, 2012 | 124.02M |
| March 31, 2012 | 116.65M |
| December 31, 2011 | 107.85M |
| September 30, 2011 | 113.42M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
387.76M
Minimum
Jun 2019
646.21M
Maximum
Dec 2023
501.33M
Average
501.69M
Median
Jun 2021
Revenue (Quarterly) Benchmarks
| Pfizer Inc | 14.25B |
| Eli Lilly and Co | 9.353B |
| Merck & Co Inc | 14.63B |
| Bristol-Myers Squibb Co | 11.48B |
| Moderna Inc | 2.813B |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 20.38M |
| Total Expenses (Quarterly) | 631.93M |
| EPS Diluted (Quarterly) | 0.11 |
| Enterprise Value | 15.52B |
| Gross Profit Margin (Quarterly) | 79.03% |
| Profit Margin (Quarterly) | 3.15% |
| Earnings Yield | 1.09% |
| Operating Earnings Yield | 1.02% |
| Normalized Earnings Yield | 1.087 |